Cargando…

Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics

Liver cancer is a common malignant tumor worldwide, which is a serious threat to the health of people. We try to investigate some mutations and clinical indicators as candidate markers for the development of liver cancer through targeted region capture technology combined with next-generation sequen...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Yunlong, Li, Hua, Zhan, Hongjie, Han, Tao, Dong, Yixuan, Tian, Caijuan, Guo, Yixian, Yan, Fang, Dai, Dong, Liu, Pengfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484954/
https://www.ncbi.nlm.nih.gov/pubmed/34604069
http://dx.doi.org/10.3389/fonc.2021.733478
_version_ 1784577434903904256
author Cui, Yunlong
Li, Hua
Zhan, Hongjie
Han, Tao
Dong, Yixuan
Tian, Caijuan
Guo, Yixian
Yan, Fang
Dai, Dong
Liu, Pengfei
author_facet Cui, Yunlong
Li, Hua
Zhan, Hongjie
Han, Tao
Dong, Yixuan
Tian, Caijuan
Guo, Yixian
Yan, Fang
Dai, Dong
Liu, Pengfei
author_sort Cui, Yunlong
collection PubMed
description Liver cancer is a common malignant tumor worldwide, which is a serious threat to the health of people. We try to investigate some mutations and clinical indicators as candidate markers for the development of liver cancer through targeted region capture technology combined with next-generation sequencing. We collected peripheral blood and liver cancer tissue samples from 32 liver patients concurrently. The SeqCap EZ Prime Choice Probe was used to perform the targeted enrichment; this probe captures 1,000 known cancer-associated genes. We calculated the tumor mutation burden (TMB) for each patient. The high-frequency mutations and these relative genes were identified. Eventually, survival analysis was performed based on the mutations and clinical indicators. In 32 liver patients, a total of 29 high-frequency mutations were investigated. They were located in 25 genes, which were enriched in 9 cellular components (CCs), 6 molecular functions (MFs), and 21 biological processes (BPs). Among them, EZH2 c.1544A>G and CCND1 c.839A>T had the highest mutation frequency (5/32). In the protein–protein interaction (PPI) network, EZH2-DNMT3A, NOTCH1-CCND1, and ABL1-CCND1 were the top three pairs. The survival analysis showed that there were significant differences in progression-free survival (PFS) and overall survival (OS) between the Karnofsky performance score (KPS) groups. The PFS and OS in the TMB high group were higher than those in the TMB low group. OS and tumor stage had a remarkable relationship. In conclusion, EZH2 c.1544A>G and CCND1 c.839A>T might be potential biomarkers of liver cancer. TMB might be used as a prognosis and survival indicator of liver cancer.
format Online
Article
Text
id pubmed-8484954
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84849542021-10-02 Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics Cui, Yunlong Li, Hua Zhan, Hongjie Han, Tao Dong, Yixuan Tian, Caijuan Guo, Yixian Yan, Fang Dai, Dong Liu, Pengfei Front Oncol Oncology Liver cancer is a common malignant tumor worldwide, which is a serious threat to the health of people. We try to investigate some mutations and clinical indicators as candidate markers for the development of liver cancer through targeted region capture technology combined with next-generation sequencing. We collected peripheral blood and liver cancer tissue samples from 32 liver patients concurrently. The SeqCap EZ Prime Choice Probe was used to perform the targeted enrichment; this probe captures 1,000 known cancer-associated genes. We calculated the tumor mutation burden (TMB) for each patient. The high-frequency mutations and these relative genes were identified. Eventually, survival analysis was performed based on the mutations and clinical indicators. In 32 liver patients, a total of 29 high-frequency mutations were investigated. They were located in 25 genes, which were enriched in 9 cellular components (CCs), 6 molecular functions (MFs), and 21 biological processes (BPs). Among them, EZH2 c.1544A>G and CCND1 c.839A>T had the highest mutation frequency (5/32). In the protein–protein interaction (PPI) network, EZH2-DNMT3A, NOTCH1-CCND1, and ABL1-CCND1 were the top three pairs. The survival analysis showed that there were significant differences in progression-free survival (PFS) and overall survival (OS) between the Karnofsky performance score (KPS) groups. The PFS and OS in the TMB high group were higher than those in the TMB low group. OS and tumor stage had a remarkable relationship. In conclusion, EZH2 c.1544A>G and CCND1 c.839A>T might be potential biomarkers of liver cancer. TMB might be used as a prognosis and survival indicator of liver cancer. Frontiers Media S.A. 2021-09-17 /pmc/articles/PMC8484954/ /pubmed/34604069 http://dx.doi.org/10.3389/fonc.2021.733478 Text en Copyright © 2021 Cui, Li, Zhan, Han, Dong, Tian, Guo, Yan, Dai and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Cui, Yunlong
Li, Hua
Zhan, Hongjie
Han, Tao
Dong, Yixuan
Tian, Caijuan
Guo, Yixian
Yan, Fang
Dai, Dong
Liu, Pengfei
Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics
title Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics
title_full Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics
title_fullStr Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics
title_full_unstemmed Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics
title_short Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics
title_sort identification of potential biomarkers for liver cancer through gene mutation and clinical characteristics
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484954/
https://www.ncbi.nlm.nih.gov/pubmed/34604069
http://dx.doi.org/10.3389/fonc.2021.733478
work_keys_str_mv AT cuiyunlong identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics
AT lihua identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics
AT zhanhongjie identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics
AT hantao identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics
AT dongyixuan identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics
AT tiancaijuan identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics
AT guoyixian identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics
AT yanfang identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics
AT daidong identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics
AT liupengfei identificationofpotentialbiomarkersforlivercancerthroughgenemutationandclinicalcharacteristics